Fabs-in-tandem immunoglobulin and uses thereof
C Wu - US Patent 11,421,028, 2022 - Google Patents
The present invention provides multivalent and multispecific binding proteins that are
capable of binding two or more antigens, or two or more epitopes. The present invention …
capable of binding two or more antigens, or two or more epitopes. The present invention …
EGFR binding molecules
M Tuna, K Leung, H Sun, M Medcalf… - US Patent 11,629,193, 2023 - Google Patents
US11629193B2 - EGFR binding molecules - Google Patents US11629193B2 - EGFR
binding molecules - Google Patents EGFR binding molecules Download PDF Info …
binding molecules - Google Patents EGFR binding molecules Download PDF Info …
FC binding fragments comprising a PD-L1 antigen-binding site
M Tuna, FW Van Horck, R FIEHLER, M Faroudi… - US Patent …, 2023 - Google Patents
C07K16/2827—Immunoglobulins [IGs], eg monoclonal or polyclonal antibodies against
material from animals or humans against receptors, cell surface antigens or cell surface …
material from animals or humans against receptors, cell surface antigens or cell surface …
LAG-3 binding members
M Tuna, FW Van Horck, KL Everett, M Gaspar… - US Patent …, 2022 - Google Patents
Kraman et al.,“A LAG-3/PD-L1 bispecific antibody inhibits tumor growth in two syngeneic
colon carcinoma models.” Retrieved from http://www. f-star. com/media/73722/A-LAG-3-PD …
colon carcinoma models.” Retrieved from http://www. f-star. com/media/73722/A-LAG-3-PD …
High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
X Wu, G Shiyong, C Wu - US Patent 12,060,425, 2024 - Google Patents
High-affinity antibodies recognizing Programmed Death Ligand-1 (PD-1) and Lymphocyte
Activation Gene 3 protein (LAG-3) are disclosed. Binding sites from humanized anti-PD-1 …
Activation Gene 3 protein (LAG-3) are disclosed. Binding sites from humanized anti-PD-1 …